TERN•benzinga•
Terns Pharmaceuticals Selected For Oral Presentation At EHA Congress For Preclinical Data On Novel Allosteric BCR-ABL Inhibitor TERN-701
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga